Genmab A/S Files 6-K on Share Transactions
Ticker: GNMSF · Form: 6-K · Filed: Dec 1, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, shares, securities
TL;DR
Genmab filed a 6-K on Dec 1, 2025, detailing share transactions; it's now part of their S-8 filings.
AI Summary
On December 1, 2025, Genmab A/S filed a Form 6-K, reporting transactions with shares and linked securities. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
Why It Matters
This filing provides transparency regarding Genmab's share and linked security transactions, which is important for investors to understand potential impacts on the company's stock and capital structure.
Risk Assessment
Risk Level: low — This is a routine disclosure filing (6-K) that incorporates previous announcements, not a filing indicating new material events or financial distress.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
- 333-284876 (dollar_amount) — S-8 Registration Statement File Number
- December 1, 2025 (date) — Filing Date
FAQ
What type of filing is Genmab A/S submitting on December 1, 2025?
Genmab A/S is submitting a Form 6-K, which is a Report of Foreign Private Issuer.
What is the purpose of this Form 6-K filing?
This Form 6-K is to report transactions with shares and linked securities in Genmab A/S, as detailed in an exhibit dated December 1, 2025.
How does this filing relate to Genmab's other SEC filings?
This Form 6-K is deemed to be incorporated by reference into Genmab A/S's registration statements on Form S-8.
Which specific Form S-8 registration statements will this 6-K be incorporated into?
This 6-K will be incorporated into Form S-8 registration statements with File Numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 15.5 · Accepted 2025-12-01 16:46:02
Filing Documents
- gmab_20251201xx6k.htm (6-K) — 13KB
- gmab_20251201xxex99d1.htm (EX-99.1) — 168KB
- genmab_logoa.jpg (GRAPHIC) — 56KB
- 0001434265-25-000106.txt ( ) — 255KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated December 1, 2025 Transactions With Shares and Linked Securities in Genmab AS Made by Managerial Employees and Their Closely Associated Persons SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE DECEMBER 1, 2025